MERAIODE: A Phase II Redifferentiation Trial with Trametinib and I in Metastatic Radioactive Iodine Refractory Mutated Differentiated Thyroid Cancer.

Address: Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.; Department of Endocrinology, Diabetology, Nutrition and Therapeutic Education, Hôpitaux Universitaires de Genève, Geneve, Switzerland.; Department of Nuclear Medicine, CLCC Antoine Lacassagne, Nice, France.; Department of Nuclear Medicine, CHU de La Timone, Marseille, France.; Department of Imaging Gustave Roussy and University Paris Saclay, Villejuif, France.; Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon, France.; Department of Nuclear Medicine UICT Oncopole, CLCC Institut Claudius Regaud, Toulouse, France.; Department of Medical Biology and Pathology, Gustave Roussy and University Paris Saclay, Villejuif, France.; AMMICa UAR3655/US23, Gustave Roussy, Villejuif, France.; Department of Physics, Gustave Roussy and University Paris Saclay, Villejuif, France.; Department of Oncology, CHU de La Timone, Marseille, France.; Department of Oncology and Department of Nuclear Medicine, CLCC Institut Bergonié, Bordeaux, France.; Department of Epidemiology and Biostatistics, Gustave Roussy and University Paris Saclay, Villejuif, France.